Latest Breaking News On - Sales of company - Page 1 : comparemela.com

BIOSYNEX Announces the Great Success of Its Capital Increase Through Placement With Qualified Investors for an Amount of €15m 100,00% For illustration purposes, the participation of a shareholder holding 1% of the Company s share capital prior to the Transaction will be diminished to 0.91%. ADMISSION TO TRADING OF NEW SHARES The new shares will bear dividend rights and will be admitted to trading on the Euronext Growth Paris market under the same ISIN code FR0011005933 ALBIO. The settlement and delivery of the new shares and their admission to trading on the Euronext Growth Paris market are scheduled for February 2, 2021. The information presented in this press release is issued at the end of the placement of the shares by accelerated bookbuilding, which is now closed, but remains conditional on the correct execution of the settlement-delivery operations.

Australia
Japan
United-states
Paris
France-general
France
United-kingdom
Canada
Illkirch-graffenstaden
Alsace
America
French